LPL Financial’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,051
| Closed | -$61.6K | – | 5715 |
|
|
2025
Q1 | $61.6K | Sell |
4,051
-22
| -0.5% | -$332 | ﹤0.01% | 5126 |
|
|
2024
Q4 | $74.8K | Sell |
4,073
-67
| -2% | -$729 | ﹤0.01% | 5049 |
|
|
2024
Q3 | $45.9K | Sell |
4,140
-60
| -1% | -$703 | ﹤0.01% | 5008 |
|
|
2024
Q2 | $39K | Buy |
4,200
+12
| +0.3% | +$286 | ﹤0.01% | 4869 |
|
|
2024
Q1 | $137K | Sell |
4,188
-132
| -3% | -$3.42K | ﹤0.01% | 4605 |
|
|
2023
Q4 | $116K | Sell |
4,320
-487
| -10% | -$20.2K | ﹤0.01% | 4524 |
|
|
2023
Q3 | $291K | Sell |
4,807
-3
| -0.1% | -$281 | ﹤0.01% | 3951 |
|
|
2023
Q2 | $490K | Sell |
4,810
-47
| -1% | -$6.47K | ﹤0.01% | 3461 |
|
|
2023
Q1 | $859K | Sell |
4,857
-28
| -0.6% | -$9.38K | ﹤0.01% | 2863 |
|
|
2022
Q4 | $1.89M | Sell |
4,885
-62
| -1% | -$23.5K | ﹤0.01% | 2109 |
|
|
2022
Q3 | $1.67M | Buy |
4,947
+247
| +5% | +$89.5K | ﹤0.01% | 2120 |
|
|
2022
Q2 | $1.54M | Buy |
4,700
+285
| +6% | +$100K | ﹤0.01% | 2228 |
|
|
2022
Q1 | $1.93M | Sell |
4,415
-21
| -0.5% | -$8.62K | ﹤0.01% | 2084 |
|
|
2021
Q4 | $1.95M | Sell |
4,436
-211
| -5% | -$106K | ﹤0.01% | 2114 |
|
|
2021
Q3 | $2.58M | Buy |
4,647
+282
| +6% | +$141K | ﹤0.01% | 1859 |
|
|
2021
Q2 | $2.24M | Buy |
4,365
+221
| +5% | +$140K | ﹤0.01% | 1884 |
|
|
2021
Q1 | $3.24M | Sell |
4,144
-24
| -0.6% | -$16.4K | ﹤0.01% | 1517 |
|
|
2020
Q4 | $2.27M | Buy |
4,168
+14
| +0.3% | +$7.34K | ﹤0.01% | 1595 |
|
|
2020
Q3 | $1.9M | Sell |
4,154
-60
| -1% | -$34.9K | ﹤0.01% | 1489 |
|
|
2020
Q2 | $2.59M | Buy |
4,214
+73
| +2% | +$40.3K | ﹤0.01% | 1212 |
|
|
2020
Q1 | $1.97M | Buy |
4,141
+19
| +0.5% | +$10.3K | ﹤0.01% | 1200 |
|
|
2019
Q4 | $2.39M | Buy |
4,122
+332
| +9% | +$233K | ﹤0.01% | 1238 |
|
|
2019
Q3 | $2.49M | Sell |
3,790
-15
| -0.4% | -$12.5K | 0.01% | 1120 |
|
|
2019
Q2 | $2.94M | Buy |
3,805
+221
| +6% | +$155K | 0.01% | 1030 |
|
|
2019
Q1 | $2.53M | Buy |
3,584
+220
| +7% | +$132K | 0.01% | 1064 |
|
|
2018
Q4 | $1.57M | Sell |
3,364
-13
| -0.4% | -$8.39K | ﹤0.01% | 1213 |
|
|
2018
Q3 | $2.91M | Sell |
3,377
-24
| -0.7% | -$17.3K | 0.01% | 966 |
|
|
2018
Q2 | $2.34M | Buy |
3,401
+274
| +9% | +$139K | 0.01% | 1036 |
|
|
2018
Q1 | $1.39M | Buy |
3,127
+1,065
| +52% | +$517K | ﹤0.01% | 1361 |
|
|
2017
Q4 | $909K | Buy |
2,062
+502
| +32% | +$229K | ﹤0.01% | 1590 |
|
|
2017
Q3 | $769K | Sell |
1,560
-72
| -4% | -$36.1K | ﹤0.01% | 1627 |
|
|
2017
Q2 | $904K | Buy |
1,632
+884
| +118% | +$561K | ﹤0.01% | 1438 |
|
|
2017
Q1 | $482K | Buy |
+748
| New | +$400K | ﹤0.01% | 1833 |
|
Other funds holding TVRD
SPC
6CM
FCM
LPL Financial's TVRD Position: Q2 2025 in Review
LPL Financial sold out of Tvardi Therapeutics (TVRD) in Q2 2025, closing a stake of 4,051 shares — an estimated $61.6K sold.
LPL Financial first reported a position in TVRD in Q1 2017 and held it in 33 quarters. The position peaked at $3.24M in Q1 2021. 56 funds tracked by Wall St. Rank hold TVRD as of Q2 2025.
- LPL Financial reported no remaining Tvardi Therapeutics position as of Q2 2025 after selling out during the quarter.
- LPL Financial sold 4,051 Tvardi Therapeutics shares in Q2 2025, an estimated $61.6K.
- LPL Financial first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 33 quarters.
- LPL Financial's Tvardi Therapeutics position peaked at $3.24M in Q1 2021.
- 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2025.
Based on LPL Financial's 13F filing for Q2 2025, filed 12 Aug 2025.